Literature DB >> 3166890

Development of drug resistance in a human epidermoid lung carcinoma xenograft line.

J Mattern1, M Bak, K H Hoever, M Volm.   

Abstract

The development of resistance to vincristine, actinomycin D and cisplatin has been examined in a human epidermoid lung carcinoma xenograft line (HXL 55) growing in nude mice. Treatment of HXL 55 with 1 mg kg-1 vincristine or 0.5 mg kg-1 actinomycin D once in each in vivo passage resulted in a rapid reduction in tumour responsiveness to these drugs. A partial resistance was already acquired at the 2nd transplant generation. In contrast, a gradual decrease in therapeutic response was observed with 10 mg kg-1 cisplatin. Irradiation with a local dose of 10 Gy induced no resistance. The three induced drug-resistant sublines were characterized in terms of the time course of development of resistance, the degree of induced resistance, cross-resistance, growth rate and stability of the phenotype.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3166890      PMCID: PMC2246496          DOI: 10.1038/bjc.1988.155

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  Development of resistance to rubidazone (NSC-164011) in Ehrlich ascites tumor in vivo.

Authors:  T Skovsgaard
Journal:  Cancer Chemother Rep       Date:  1975 Mar-Apr

2.  The therapeutic response of three human tumor lines maintained in immune-suppressed mice.

Authors:  L Kopper; G G Steel
Journal:  Cancer Res       Date:  1975-10       Impact factor: 12.701

3.  Acquisition of multiple drug resistance by CCRF-CEM cells selected for different degrees of resistance to vincristine.

Authors:  V Conter; W T Beck
Journal:  Cancer Treat Rep       Date:  1984-06

Review 4.  Patterns of resistance and therapeutic synergism among alkylating agents.

Authors:  F M Schabel; M W Trader; W R Laster; G P Wheeler; M H Witt
Journal:  Antibiot Chemother (1971)       Date:  1978

Review 5.  Nitrosoureas: a review of experimental antitumor activity.

Authors:  F M Schabel
Journal:  Cancer Treat Rep       Date:  1976-06

6.  In situ selection of a human rhabdomyosarcoma resistant to vincristine with altered beta-tubulins.

Authors:  J A Houghton; P J Houghton; B J Hazelton; E C Douglass
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

7.  Growth of human bronchial carcinomas in nude mice.

Authors:  J Mattern; S Jäger; J Sonka; K Wayss; M Volm
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

8.  Development of drug resistance in a murine mammary tumour.

Authors:  T J McMillan; T C Stephens; G G Steel
Journal:  Br J Cancer       Date:  1985-12       Impact factor: 7.640

9.  Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells.

Authors:  P R Twentyman; N E Fox; K A Wright; N M Bleehen
Journal:  Br J Cancer       Date:  1986-04       Impact factor: 7.640

10.  Induced and inherent resistance to alkylating agents in human small-cell bronchial carcinoma xenografts.

Authors:  R Berman; G G Steel
Journal:  Br J Cancer       Date:  1984-04       Impact factor: 7.640

View more
  3 in total

1.  High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma.

Authors:  Kenny Kwok-Hei Yu; Jessica T Taylor; Omar N Pathmanaban; Amir Saam Youshani; Deniz Beyit; Joanna Dutko-Gwozdz; Roderick Benson; Gareth Griffiths; Ian Peers; Peter Cueppens; Brian A Telfer; Kaye J Williams; Catherine McBain; Ian D Kamaly-Asl; Brian W Bigger
Journal:  PLoS One       Date:  2018-03-02       Impact factor: 3.240

2.  Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenografts.

Authors:  W Budach; V Budach; M Stuschke; B Schmauder; P Reipke; M E Scheulen
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

3.  Establishment of drug resistance in human gastric and colon carcinoma xenograft lines.

Authors:  T Satta; K Isobe; M Yamauchi; I Nakashima; S Akiyama; K Itou; T Watanabe; H Takagi
Journal:  Jpn J Cancer Res       Date:  1991-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.